Interstitial lung diseases after hematopoietic stem cell transplantation: New pattern of lung chronic graft-versus-host disease? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Interstitial Lung Disorders Following Hematopoietic Stem Cell Transplantation: A Novel Presentation of Chronic Graft-Versus-Host Disease?

  • By

  • Gabrielle Archer

  • Ingrid Berger

  • Louise Bondeelle

  • Constance de Margerie-Mellon

  • Stéphane Cassonnet

  • Régis Peffault de Latour

  • David Michonneau

  • Sylvie Chevret

  • Anne Bergeron

  • October 29, 2022

Share

  • 1

    Chronic graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (HSCT) affecting prognosis.

  • 2

    Bronchiolitis obliterans syndrome (BOS) is the only formally recognized lung manifestation of chronic GVHD, characterized by obstructive lung disease.

  • 3

    Interstitial lung disease (ILD) has a cumulative incidence of 5% post-HSCT and is associated with restrictive lung disease and chronic GVHD.

  • 4

    Histological patterns of post-HSCT ILD include organizing pneumonia and nonspecific interstitial pneumonia, often coexisting with obliterative bronchiolitis.

  • 5

    The study aims to compare characteristics and outcomes of patients with ILD and BOS after HSCT, utilizing a retrospective observational cohort.

Original Source(s)

Interstitial lung diseases after hematopoietic stem cell transplantation: New pattern of lung chronic graft-versus-host disease?

  • by Gabrielle Archer, Ingrid Berger, Louise Bondeelle, Constance de Margerie-Mellon, Stéphane Cassonnet, Régis Peffault de Latour, David Michonneau, Sylvie Chevret, Anne Bergeron

  • October 29, 2022

Related Content

Zanubrutinib monotherapy in CD79B-mutated relapsed or refractory diffuse large B-cell lymphoma: A multicenter Phase 2 study

“A long bristling road full of adventure, full of discovery” gene therapy approaches in transfusion-dependent thalassemia: The EHA-EBMT consensus paper

Musings From the Power List: Jason Bock

Jason Bock shares his outlook on RNA-targeting therapies, personalized medicine, and the future of drug development